Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 425,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $26.67, for a total value of $11,334,750.00. Following the transaction, the director directly owned 15,928,113 shares of the company’s stock, valued at $424,802,773.71. The trade was a 2.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Friday, February 13th, Daniel Allen Gold sold 375,784 shares of Roivant Sciences stock. The stock was sold at an average price of $26.50, for a total value of $9,958,276.00.
• On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The shares were sold at an average price of $23.07, for a total value of $17,933,049.24.
• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The shares were sold at an average price of $23.04, for a total value of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.23, for a total transaction of $26,299,000.00.

Roivant Sciences Stock Down 1.1%

Roivant Sciences stock opened at $26.45 on Friday. The company has a fifty day simple moving average of $22.71 and a 200-day simple moving average of $18.31. The firm has a market capitalization of $18.40 billion, a price-to-earnings ratio of -22.61 and a beta of 1.22. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $27.94.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds have recently modified their holdings of the business. Penn Davis Mcfarland Inc. lifted its position in shares of Roivant Sciences by 10.1% during the third quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock worth $28,173,000 after purchasing an additional 170,456 shares during the last quarter. Valeo Financial Advisors LLC acquired a new stake in Roivant Sciences during the second quarter valued at approximately $1,145,000. IFG Advisory LLC bought a new position in Roivant Sciences during the 2nd quarter worth approximately $255,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Roivant Sciences in the 2nd quarter worth approximately $3,064,000. Finally, Franklin Resources Inc. acquired a new position in shares of Roivant Sciences in the 2nd quarter worth approximately $997,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences News Summary

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
• Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
• Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
• Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near?term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
• Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
• Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near?term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update

Analysts Set New Price Targets

Several research analysts have recently weighed in on ROIV shares. Weiss Ratings cut Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research report on Saturday, February 7th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. HC Wainwright raised their target price on Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Citigroup boosted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.